Takeda Cleared To Market Combo Drug For Treating Type 2 Diabetes
This article was originally published in PharmAsia News
Takeda Pharmaceutical said it has received Japanese approval to expand the market for its Nesina (algogliptin) in combination with other drugs for treating type 2 diabetes. The other drugs in the combination are sulfonylurea and biguanide
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.